A detailed history of Manufacturers Life Insurance Company, The transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 23,740 shares of VTYX stock, worth $53,889. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,740
Previous 24,349 2.5%
Holding current value
$53,889
Previous $56,000 8.93%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$1.85 - $3.2 $1,126 - $1,948
-609 Reduced 2.5%
23,740 $51,000
Q2 2024

Aug 14, 2024

BUY
$2.31 - $5.59 $16,391 - $39,666
7,096 Added 41.13%
24,349 $56,000
Q1 2024

May 14, 2024

BUY
$1.9 - $10.13 $6,610 - $35,242
3,479 Added 25.26%
17,253 $94,000
Q4 2023

Feb 13, 2024

SELL
$2.08 - $31.18 $130,079 - $1.95 Million
-62,538 Reduced 81.95%
13,774 $34,000
Q3 2023

Nov 15, 2023

SELL
$29.8 - $40.3 $373,334 - $504,878
-12,528 Reduced 14.1%
76,312 $2.65 Million
Q2 2023

Aug 11, 2023

BUY
$28.53 - $39.55 $1.36 Million - $1.89 Million
47,760 Added 116.26%
88,840 $2.91 Million
Q1 2023

May 15, 2023

BUY
$29.51 - $46.65 $802,642 - $1.27 Million
27,199 Added 66.21%
68,279 $2.29 Million
Q4 2022

Aug 11, 2023

BUY
$24.16 - $36.38 $316,979 - $477,305
13,120 Added 46.92%
41,080 $1.35 Million
Q4 2022

Feb 13, 2023

BUY
$24.16 - $36.38 $316,979 - $477,305
13,120 Added 46.92%
41,080 $1.35 Million
Q3 2022

Aug 11, 2023

SELL
$12.64 - $38.7 $509,632 - $1.56 Million
-40,319 Reduced 59.05%
27,960 $976,000
Q3 2022

Nov 03, 2022

BUY
$12.64 - $38.7 $353,414 - $1.08 Million
27,960 New
27,960 $980,000

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $128M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.